Healios K.K. (OTCMKTS:HLOSF – Get Rating) is one of 406 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Healios K.K. to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, institutional ownership, dividends and earnings.
Insider and Institutional Ownership
20.3% of Healios K.K. shares are owned by institutional investors. Comparatively, 27.9% of shares of all “Biotechnology” companies are owned by institutional investors. 23.9% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations for Healios K.K. and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Healios K.K. | 0 | 0 | 0 | 0 | N/A |
| Healios K.K. Competitors | 830 | 1971 | 6189 | 80 | 2.61 |
Valuation & Earnings
This table compares Healios K.K. and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Healios K.K. | N/A | N/A | -32.57 |
| Healios K.K. Competitors | $373.71 million | $53.84 million | 19.12 |
Healios K.K.’s competitors have higher revenue and earnings than Healios K.K.. Healios K.K. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Healios K.K. and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Healios K.K. | N/A | N/A | N/A |
| Healios K.K. Competitors | -477.67% | -67.10% | -24.73% |
Summary
Healios K.K. competitors beat Healios K.K. on 5 of the 8 factors compared.
Healios K.K. Company Profile
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
